Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812294 | 1.00 | ACACB (0.45) | ACACBEPHX2PDE4DPDE4APDE4B | |
| SCHEMBL17316337 | 0.88 | ACACB (0.48) | ACACBEPHX2SRD5A2CA2CAMK2A | |
| SCHEMBL1808785 | 0.85 | LIPE (0.49) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1808783 | 0.85 | LIPE (0.49) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12985424 | 0.82 | EPHX2 (0.54) | ACACBEPHX2SRD5A2CA2CAMK2A | |
| SCHEMBL22657678 | 0.82 | LIPE (0.50) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8002002 | 0.81 | SLC5A2 (0.47) | ACACBEPHX2SLC5A2SLC5A1LIPG | |
| SCHEMBL19859012 | 0.80 | ALDH1A1 (0.57) | ACACBEPHX2PDE4DPDE4APDE4B | |
| SCHEMBL19859011 | 0.80 | ALDH1A1 (0.57) | ACACBEPHX2PDE4DPDE4APDE4B | |
| SCHEMBL19859013 | 0.80 | ALDH1A1 (0.57) | ACACBEPHX2PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011061590-A1 | NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | ACACB 4294/4885EPHX2 3023/4885PDE4D 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.